Buochs

Hidradenitis suppurativa (HS) is a chronic and often painful skin disease that causes lumps, abscesses, and scars in areas like under the breasts, armpits, inner thighs, groin, and buttocks. Researchers are evaluating the investigational drug lutikizumab compared to placebo in adults and adolescents with moderate to severe HS. This study aims to assess the disease activity and safety of lutikizumab in a Phase 3 clinical trial involving about 1280 participants worldwide.

This research aims to evaluate the effects of povorcitinib on reducing itch and improving skin lesions in adults with prurigo nodularis, a chronic skin condition characterized by itchy nodules. The study is a Phase 3 trial designed to assess the safety and efficacy of this treatment compared to a placebo in participants aged 18 to 75 years with a confirmed diagnosis of prurigo nodularis lasting at least three months. Participants will receive either oral povorcitinib tablets or placebo tablets as part of the randomized, double-blind study. Key eligibility includes having significant itch severity and at least 20 pruriginous lesions on multiple body regions. The study monitors the treatment effects over 24 weeks, focusing on improvements in itch intensity and skin lesion severity. During the study, participants will be closely monitored for changes in their itch scores and skin condition. Researchers will assess the proportion of participants achieving specified improvements by Week 24. Safety and tolerability will also be evaluated throughout the trial. Participants will undergo regular assessments including clinical evaluations, laboratory tests, and adherence monitoring to track progress and any side effects over the course of the study.

This research focuses on participants with Hidradenitis Suppurativa (HS) who have previously taken part in specific Incyte-sponsored clinical trials of povorcitinib. The study is a Phase 3b rollover trial designed to continue monitoring these individuals to gather further information on the treatment. It aims to evaluate the safety of povorcitinib over an extended period, including the proportion of participants experiencing treatment-emergent adverse events for up to about three years. Participants will continue taking the study drug povorcitinib orally as specified by the study protocol. This rollover study includes individuals who completed the treatment period in the parent studies without safety or tolerability issues and who showed clinical benefit from povorcitinib. During this study, participants will follow the protocol-defined dosing and procedures while avoiding pregnancy or fathering children as required. Throughout the study, participants will attend scheduled visits and assessments to monitor their health and treatment effects. Researchers will track adverse events and adherence to the treatment plan. The study involves ongoing evaluation for up to approximately three years to ensure safety and collect important long-term data on povorcitinib use in this group of patients with HS.

Researchers are studying patients with moderate-to-severe atopic dermatitis (AD), a common chronic inflammatory skin disease that significantly affects quality of life and has a high socioeconomic impact. This Swiss national, prospective, non-interventional, multicenter registry aims to fill the gap in detailed data about AD management. The study focuses on documenting the medical care of these patients to evaluate treatment appropriateness and to collect information on psychosocial effects, epidemiology, risk factors, and comorbidities. The study includes children aged 12 years and older, adolescents, and adults with moderate-to-severe AD. No study-related interventions or treatments are given. Participants are followed prospectively for at least 24 months, with no maximum follow-up duration intended. During this time, standardized visits collect detailed patient characteristics, clinical data, patient-reported outcomes, reasons for treatment decisions, and satisfaction with therapies. The study observes the use of approved systemic drugs and other treatments as they occur in routine medical care. Participants will undergo regular evaluations to record disease status, treatment use, and quality of life impacts. Researchers will monitor the type of systemic therapy used over 24 months as the main outcome. The study seeks to establish a clinical research network and support future projects by providing comprehensive, real-world data. Patient consent is required, and those enrolled contribute data through follow-up visits without additional treatments imposed by the study.